Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (BBMPI03)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02240537
Recruitment Status : Unknown
Verified April 2016 by Benovus Bio, Inc..
Recruitment status was:  Active, not recruiting
First Posted : September 15, 2014
Last Update Posted : April 19, 2016
Information provided by (Responsible Party):
Benovus Bio, Inc.

Brief Summary:
The study is designed to evaluate safety, immunogenicity, and preliminary anti-tumor activity of a multi-peptide immunotherapy (BB-MPI-03) at three peptide+adjuvant dose levels. The peptides stimulate cytotoxic T-cells targeting oncofetal antigen (OFA). Subjects with AML, MM, sMM, or MDS who are off treatment and with stable disease or better, or who are not eligible for or refuse allogeneic HSCT are to be enrolled. The study will be conducted at 2 to 4 study centers in the US.

Condition or disease Intervention/treatment Phase
Acute Myelogenous Leukemia (AML) Multiple Myeloma (MM) Myelodysplastic Syndrome (MDS) Smoldering Multiple Myeloma (sMM) Drug: Sargramostim Drug: BB-MPI-03 Drug: Montanide Phase 1

Detailed Description:

The current study is a Phase I, open-label, multi-center, dose escalation study designed to evaluate safety, immunogencity, and potential anti-tumor activity of BB-MPI-03 at three peptide plus adjuvant dose levels. Subjects with acute myelogenous leukemia (AML), multiple myeloma (MM), smoldering multiple myeloma (sMM), or myelodysplastic syndrome (MDS) who are off treatment and with stable disease or better or who are not eligible for or refuse allogeneic hematopoietic stem cell transplantation (HSCT) are to be enrolled. The study will be conducted at 2 to 4 study centers in the United States (US).

The study employs a sequential group, open-label, 3+3 dose- escalation design to determine the safety and MTD of BB- MPI-03.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of an Oncofetal Antigen ("OFA") Multi-Peptide Immunotherapy ("BBMPI03") in Subjects With Hematologic Cancer
Study Start Date : January 2015
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : June 2017

Arm Intervention/treatment
Experimental: Open Label Treatment Arm
BB-MPI-03 peptides plus montanide plus sargramostim
Drug: Sargramostim
Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
Other Name: Leukine

Drug: BB-MPI-03
Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
Other Name: Multi-peptide Immunotherapy

Drug: Montanide

Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.

Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration.

Other Name: Emulsion

Primary Outcome Measures :
  1. Determine the safety, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and optimal biologic dose (OBD) of BB-MPI-03 and adjuvants in subjects with hematologic cancers who are off treatment and with stable disease (SD) or better. [ Time Frame: 6 months treatment, 6 months follow-up ]

    The safety and tolerability of BB-MPI-03 in Montanide emulsion preceded by sargramostim will be measured by:

    • The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), DLTs, and AEs leading to study vaccine discontinuation.
    • The proportion of subjects requiring a modification of the study treatment dose or schedule.
    • Change from baseline in absolute neutrophil counts (ANC) and platelet counts.
    • The proportion of subjects with local injection site reactivity.
    • Proportion of subjects experiencing infections or fevers requiring hospitalization and/or intravenous (IV) antibiotics.

Secondary Outcome Measures :
  1. Determine the in vivo cellular immune response profile of BB-MPI-03 and adjuvants in subjects who receive 5 and 6 intradermal (ID) injections over a 6- month period. [ Time Frame: 12 Months ]

    Immunologic responses (change from Baseline) will be assessed by:

    • DTH reaction to the peptides, as measured and photographed at 7 months using the "ballpoint pen" method.
    • Peptide-specific T-cell proliferation to ELISPOT and tetramer assay.
    • Level of OFA expression on tumor cells at Month 7.
    • Anti-peptide (anti-OFA) antibodies in the serum. These parameters will be measured at D15, D29, M2, M3, M6, M9, and M12 and compared to pre-treatment Baseline. DTH reaction to the peptides and OFA expression will be measured and recorded at 1 month after the last injection (M7).

  2. Evaluate any anti-tumor activity of BB-MPI-03 and adjuvants as assessed by disease reduction and lack of disease progression during and after treatment. [ Time Frame: 12 Months ]

    The anti-tumor activity of BB MPI 03 in Montanide emulsion preceded by sargramostim will be measured by:

    Time to progression (TTP) Overall response rate at Month 7 Best Overall Response

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

a. History of morphologically confirmed AML w/ classification other than WHO Acute Promyelocytic Leukemia (FAB M3), based on bone marrow examination.

i. not a candidate for allogeneic HSCT or no intention to move to HSCT at time of enrollment.

ii. Patient's AML could be in morphologic CR or no further cytotoxic chemotherapy is currently being considered.

iii. Completed consolidation chemotherapy, if available and/or appropriate for patient.

iv. Can have history of allogeneic HSCT transplant, but must be off immunosuppression for at least 2 wks. before enrollment and w/o GVHD and/or toxicities from HSCT.

b. Diagnosed in past 5 years w/ smoldering MM at high risk of progressing to symptomatic MM.

i. Diagnosis defined as: Bone marrow infiltration with plasma cells (PCs) ≥10% and presence of a monoclonal component, Ig G ≥3 g/dl or IgA ≥2 g/dl or Bence-Jones proteinuria >1 g/dl and absence of lytic lesions on skeletal survey, absence of hypercalcemia (corrected calcium <11 mg/dl), absence of renal failure (creatinine ≤1.5 x ULN), and absence of anemia (hemoglobin >10 g/dl or not 2 g/dl below LLN).

ii. Must meet one of following:

  • ≥10% PCs in bone marrow and IgG ≥3 g/dl or IgA ≥2 g/dl,
  • ≥10% PCs in bone marrow and serum FLC ratio (involved : uninvolved) >100 in blood, or
  • IgG ≥3 g/dl or IgA ≥2 g/dl and FLC ratio (involved: uninvolved) >100 in blood. c. MM post-treatment disease that is clinically stable and does not require treatment at least 4 weeks prior to enrollment.

    i. At least one line of treatment and achieved at least PR by IMWG ii. Stable disease or better per IMWG based on 2 subsequent assessments at least one month apart d. history of morphologically confirmed MDS i. previously received at least one treatment for MDS, including but not limited to chemotherapy or hypomethylating agent(s). Subjects may be previously untreated if they refuse treatment with or are not appropriate candidates for chemotherapy or hypomethylating agent(s) in the investigator's opinion.

ii. intermediate, high, or very high risk MDS by IPSS-r iii. No curative intent option of allogeneic HSCT or refused consideration for allogeneic HSCT iv. Could have history of allogeneic HSCT transplant and relapsed, but must be off immunosuppression for at least 2 weeks before enrollment and without GVHD and/or toxicities from HSCT.

2. Low, moderate, to high levels of OFA expression by IHC analysis of tumor specimens.

3. HLA-A*02 haplotype.

4. ECOG performance status 0 to 2.

5. 18 years or older.

6. life expectancy ≥3 months.

7. Has following laboratory parameters w/in 28 days:

  • ANC ≥500/mm3
  • ALC >500/mm3
  • PLT ≥25,000/mm3 and may be transfused
  • Hgb >8 g/dL (may have been transfused)
  • Serum creatinine ≤1.5 x ULN
  • Total bilirubin ≤2.0 mg/dL, unless elevated bilirubin due to Gilbert's syndrome
  • ALT and AST less than 5×ULN

    8. If female of child-bearing potential, negative serum pregnancy test result w/in 28 of D1 and agree to abstain from heterosexual intercourse or use acceptable method of birth control (hormonal or barrier method) from Screening through 30 days after last dose

    9. If male having sexual contact with a female of child-bearing potential, agrees to use a latex condom dor agrees to ensure partner uses an acceptable method of birth control (hormonal or barrier method)from Screening through 30 days after last dose

    10. Able to provide written informed consent

Exclusion Criteria

  1. Received chemotherapy, biological therapy, or radiation therapy less than one month before D1
  2. No prior history of active CNS involvement
  3. Grade 2 or higher peripheral neuropathy w/in 28 days
  4. Acute promyelocytic leukemia (FAB M3)
  5. Other active systemic malignancy treated w/ cytotoxic chemotherapy in previous 12 mos.
  6. Monoclonal gammopathy of undetermined significance
  7. For smoldering MM, baseline bone lesions or plasmacytomas
  8. For smoldering MM, lytic lesions on skeletal surveys and hypercalcemia (i.e., ≥11 mg/dL)
  9. Known HIV or hepatitis virus infection
  10. Active infection requiring antibiotics
  11. History of prior or active autoimmune disease such as Lupus or rheumatoid arthritis
  12. Significant kidney or liver disease, uncontrolled severe cardiovascular or pulmonary disease, other uncontrolled medical condition that would compromise subject's ability to tolerate study treatment
  13. Received any investigational treatment w/in 30 days
  14. Receiving systemic glucocorticosteroid >10 mg daily. Concurrent use after registration on study should be restricted to equivalent of prednisone 10 mg per day. Prior or concurrent topical or localized glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted. Subject requiring routine use of steroid inhalers are not eligible.
  15. Major surgery w/in 4 wks.
  16. G-CSF w/in 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02240537

Layout table for location information
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Virginia
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Sponsors and Collaborators
Benovus Bio, Inc.

Layout table for additonal information
Responsible Party: Benovus Bio, Inc. Identifier: NCT02240537    
Other Study ID Numbers: BBMPI03-Hem-01
First Posted: September 15, 2014    Key Record Dates
Last Update Posted: April 19, 2016
Last Verified: April 2016
Keywords provided by Benovus Bio, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Leukemia, Myeloid, Acute
Hematologic Neoplasms
Smoldering Multiple Myeloma
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bone Marrow Diseases
Precancerous Conditions
Leukemia, Myeloid
Neoplasms by Site
Immunologic Factors
Physiological Effects of Drugs